Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. [Ann Allergy Asthma Immunol] Journal article | | Title | Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. | | Author(s) | Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM | | Institution | University of Iowa, Iowa City, USA. jweiler@compleware.com | | Source | Ann Allergy Asthma Immunol 2005 Jan; 94(1):65-72. | | MeSH | Administration, Inhalation
Adolescent
Adult
Albuterol
Androstadienes
Anti-Asthmatic Agents
Asthma, Exercise-Induced
Child
Double-Blind Method
Exercise Test
Female
Forced Expiratory Volume
Humans
Male
Middle Aged
Research Support, Non-U.S. Gov't
| | Abstract | BACKGROUND: Exercise is a common trigger of asthma symptoms in patients with persistent asthma.
OBJECTIVE: To evaluate the protective effect of fluticasone/salmeterol against exercise-induced bronchospasm.
METHODS: Multicenter, randomized, double-blind, parallel-group trial of 192 asthma patients who used moderate-dose inhaled corticosteroids. Patients (aged 12-50 years; mean forced expiratory volume in 1 second [FEV1], 78% of predicted at baseline) were randomized to receive fluticasone/salmeterol (250/50 microg twice daily) or fluticasone alone (250 microg twice daily) via Diskus for 4 weeks. Exercise challenge tests were performed 1 and 8.5 hours after administration of the first (day 1) and last (week 4) doses of blinded study medication.
RESULTS: On day 1 and at week 4, mean +/- SEM values for the maximal percentage decline in FEV1 1 hour after drug administration were 11.4% +/- 1.5% and 10.9% +/- 1.5% for fluticasone/salmeterol compared with 20.0% +/- 1.7% and 18.4% +/- 1.8% for fluticasone (P < .001). At 8.5 hours, mean +/- SEM values on day 1 and at week 4 were 11.6% +/- 1.4% and 8.9% +/1.1%, respectively, for fluticasone/salmeterol and 12.6% +/- 1.6% and 12.9% +/- 1.4%, respectively, for fluticasone (P = .01 at week 4). More fluticasone-treated patients did not complete the 8.5-hour exercise challenges (36% on day 1 and 33% at week 4) compared with the fluticasone/salmeterol group (18% each) (P < or = .01). Improvements in peak expiratory flow rate and albuterol rescue-free days were significantly greater with fluticasone/salmeterol vs fluticasone over weeks 1 to 4 (P < or = .03).
CONCLUSIONS: Consistent with the improvements in other measures of asthma control, long-term fluticasone/salmeterol therapy also provided protection against exercise-induced bronchospasm in patients with persistent asthma. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 15702819 |
|
|
| |
Advertise on this site.
| | |
|
